Signs and Symptoms of Chest Diseases: Cough |

A Systematic Review and Meta-analysis of Randomized, Double-Blind, Placebo-Controlled Trials of GABAB Receptor Agonists on Regulating Human Cough FREE TO VIEW

Weili Wei, MD; Yangzi ZhangTong; Qiang Chen; Li Yu; Zhongmin Qiu
Author and Funding Information

Tongji Hospital, Tongji University School of Medicine, Shanghai, China

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;149(4_S):A549. doi:10.1016/j.chest.2016.02.573
Text Size: A A A
Published online


SESSION TYPE: Original Investigation Slide

PRESENTED ON: Sunday, April 17, 2016 at 08:30 AM - 09:30 AM

PURPOSE: There is no systematic review of randomized controlled trials of the regulation function of GABAB receptor agonists for human cough. The study objectives was to evaluated GABAB receptor agonists on regulating human cough.

METHODS: Claims data from the MEDLINE, EMBASE, LILACS, CBM, CNKI, VIP, WanFang and the Cochrane Library databases were used to conduct retrospective cohort analyses. We review articles and reference lists of relevant articles prior to 4 September 2015 (Table 1) for human with restrictions as to language of English or Chinese. Two authors independently reviewed the titles and abstracts of the retrieved studies of GABA-agonist (baclofen or arbaclofen) which were matched using Review Manager 5.3 software. Then we extracted relevant data by outcome for therapy group of GABAB receptor agonists and for the control group of placebo or medicine. The outcome data were number of subjects whose cough threshold to inhaled capsaicin C5 increased after treatment or those symptom decline. Disagreements were resolved by consensus.

RESULTS: Seven RCTs including 256 persons in total were enrolled in this study and all associated with baclofen, in which 61% of participants were patients and 39% were healthy adult volunteers (Table 2 and 3). After treatment the elevated effect on C5 or relief of cough symptoms was significant (OR13.50 (95%CI: (1.43-127.17), P =0.03) in subgroup of baclofen versus placebo. and the outcome has no statistics differences (OR1.31 (95%CI: (0.64-2.68), P =0.47) in subgroup of baclofen versus medicine (Figure 1). Baclofen was well tolerated with minimal side effects, which were specifically mentioned in two studies. Methodological biases in the design and execution of cluster randomised trials might contributed to the selection bias in this review (Figure 2.1 and 2.2).

CONCLUSIONS: We confirm the recent observation that therapy with GABAB receptor agonists (baclofen) diminishes cough reflex sensitivity in asymptomatic human subjects and increase the antitussive activity for patients of cough. Different methodological might contributed to a selection bias in our results.

CLINICAL IMPLICATIONS: For patients chronically maintained on oral baclofen for the treatment muscle spasm therapy diminishes cough reflex sensitivity. Due attention should be paid to these asymptomatic of cough for avoiding aspiration. While for patients of cough GABAB receptor agonists such as baclofen increase the antitussive activity and may represent novel therapeutic approaches for a cough hypersensitivity syndrome.

DISCLOSURE: The following authors have nothing to disclose: Weili Wei, Yangzi ZhangTong, Qiang Chen, Li Yu, Zhongmin Qiu

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Encoding of the cough reflex in anesthetized guinea pigs. Am J Physiol Regul Integr Comp Physiol 2011;300(2):R369-77.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543